72 related articles for article (PubMed ID: 17893875)
21. Tectorigenin sensitizes paclitaxel-resistant human ovarian cancer cells through downregulation of the Akt and NFκB pathway.
Yang YI; Lee KT; Park HJ; Kim TJ; Choi YS; Shih IeM; Choi JH
Carcinogenesis; 2012 Dec; 33(12):2488-98. PubMed ID: 23027625
[TBL] [Abstract][Full Text] [Related]
22. Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer.
Coukos G; Makrigiannakis A; Kang EH; Rubin SC; Albelda SM; Molnar-Kimber KL
Clin Cancer Res; 2000 Aug; 6(8):3342-53. PubMed ID: 10955822
[TBL] [Abstract][Full Text] [Related]
23. Mesothelin inhibits paclitaxel-induced apoptosis through the PI3K pathway.
Chang MC; Chen CA; Hsieh CY; Lee CN; Su YN; Hu YH; Cheng WF
Biochem J; 2009 Dec; 424(3):449-58. PubMed ID: 19747165
[TBL] [Abstract][Full Text] [Related]
24. Cyclic GMP/protein kinase G type-Iα (PKG-Iα) signaling pathway promotes CREB phosphorylation and maintains higher c-IAP1, livin, survivin, and Mcl-1 expression and the inhibition of PKG-Iα kinase activity synergizes with cisplatin in non-small cell lung cancer cells.
Wong JC; Bathina M; Fiscus RR
J Cell Biochem; 2012 Nov; 113(11):3587-98. PubMed ID: 22740515
[TBL] [Abstract][Full Text] [Related]
25. Activation of extracellular signal-regulated kinases ERK1 and ERK2 induces Bcl-xL up-regulation via inhibition of caspase activities in erythropoietin signaling.
Mori M; Uchida M; Watanabe T; Kirito K; Hatake K; Ozawa K; Komatsu N
J Cell Physiol; 2003 May; 195(2):290-7. PubMed ID: 12652655
[TBL] [Abstract][Full Text] [Related]
26. The potent peptide antagonist to angiogenesis, C16Y, and cisplatin act synergistically in the down-regulation of the Bcl-2/Bax ratio and the induction of apoptosis in human ovarian cancer cells.
Shinagawa A; Yoshida Y; Kurokawa T; Horiuchi Y; Tsuyoshi H; Orisaka M; Sawamura Y; Kleinman HK; Kotsuji F
Int J Oncol; 2011 Dec; 39(6):1359-64. PubMed ID: 21935568
[TBL] [Abstract][Full Text] [Related]
27. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
28. The role of expression of the components of proteome in the formation of molecular profile of human ovarian carcinoma A2780 cells sensitive and resistant to cisplatin.
Chekhun VF; Lukyanova NY; Urchenko OV; Kulik GI
Exp Oncol; 2005 Sep; 27(3):191-5. PubMed ID: 16244579
[TBL] [Abstract][Full Text] [Related]
29. Erythropoietin Promotes Glioblastoma via miR-451 Suppression.
Alural B; Ayyildiz ZO; Tufekci KU; Genc S; Genc K
Vitam Horm; 2017; 105():249-271. PubMed ID: 28629521
[TBL] [Abstract][Full Text] [Related]
30. Glioblastoma multiforme cells: expression of erythropoietin receptor and response to erythropoietin.
Yin D; Kawabata H; Tcherniamtchouk O; Huynh T; Black KL; Koeffler HP
Int J Oncol; 2007 Nov; 31(5):1193-8. PubMed ID: 17912447
[TBL] [Abstract][Full Text] [Related]
31. [Study of bcl-2 antisense oligodeoxynucleotides on reversal of cisplatin resistance in ovarian cancer cell line A2780/DDP].
Li M; Yu LL; Cai LQ; Wang HB; Wang ZH; Wang ZH
Zhonghua Fu Chan Ke Za Zhi; 2006 Feb; 41(2):121-5. PubMed ID: 16640863
[TBL] [Abstract][Full Text] [Related]
32. [The effect of Bcl-2 gene silencing on the sensitivity of cell line A549 to chemotherapeutic drugs].
Wang JQ; Du ZW; Gao XF; Wu M; Zhang YC; Pan Y; Wang Q; Zhang GZ
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Mar; 36(3):191-7. PubMed ID: 23856142
[TBL] [Abstract][Full Text] [Related]
33. Small inhibitor of Bcl-2, HA14-1, selectively enhanced the apoptotic effect of cisplatin by modulating Bcl-2 family members in MDA-MB-231 breast cancer cells.
Arisan ED; Kutuk O; Tezil T; Bodur C; Telci D; Basaga H
Breast Cancer Res Treat; 2010 Jan; 119(2):271-81. PubMed ID: 19238538
[TBL] [Abstract][Full Text] [Related]
34. Co-stimulation with stem cell factor and erythropoietin enhances migration of c-Kit expressing cervical cancer cells through the sustained activation of ERK1/2.
Aguilar C; Aguilar C; Lopez-Marure R; Jiménez-Sánchez A; Rocha-Zavaleta L
Mol Med Rep; 2014 May; 9(5):1895-902. PubMed ID: 24626629
[TBL] [Abstract][Full Text] [Related]
35. Does erythropoietin have a dark side? Epo signaling and cancer cells.
Sytkowski AJ
Sci STKE; 2007 Jul; 2007(395):pe38. PubMed ID: 17636183
[TBL] [Abstract][Full Text] [Related]
36. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer.
Wesarg E; Hoffarth S; Wiewrodt R; Kröll M; Biesterfeld S; Huber C; Schuler M
Int J Cancer; 2007 Dec; 121(11):2387-94. PubMed ID: 17688235
[TBL] [Abstract][Full Text] [Related]
37. [Expression of a novel biomarker, MR-1S, in ovarian carcinoma and its biological significance].
Lu RQ; Sun M; Gao X; Guo L
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):176-81. PubMed ID: 22780969
[TBL] [Abstract][Full Text] [Related]
38. SRC tyrosine kinase and multidrug resistance protein-1 inhibitions act independently but cooperatively to restore paclitaxel sensitivity to paclitaxel-resistant ovarian cancer cells.
George JA; Chen T; Taylor CC
Cancer Res; 2005 Nov; 65(22):10381-8. PubMed ID: 16288028
[TBL] [Abstract][Full Text] [Related]
39. Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids.
Frankel A; Buckman R; Kerbel RS
Cancer Res; 1997 Jun; 57(12):2388-93. PubMed ID: 9192815
[TBL] [Abstract][Full Text] [Related]
40. Acquisition of paclitaxel resistance via PI3K‑dependent epithelial‑mesenchymal transition in A2780 human ovarian cancer cells.
Du F; Wu X; Liu Y; Wang T; Qi X; Mao Y; Jiang L; Zhu Y; Chen Y; Zhu R; Han X; Jin J; Ma X; Hua D
Oncol Rep; 2013 Sep; 30(3):1113-8. PubMed ID: 23807572
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
